Inhibition of Ehrlich ascites cancer, hypoxia-inducible factor-1 alpha, and the kinase insert domain-containing receptor/ -like tyrosine kinase-binding domains of vascular endothelial growth factor by Thiazole Acetamide Derivatives.

MLA

Madhu, L., et al. “Inhibition of Ehrlich Ascites Cancer, Hypoxia-Inducible Factor-1 Alpha, and the Kinase Insert Domain-Containing Receptor/ -like Tyrosine Kinase-Binding Domains of Vascular Endothelial Growth Factor by Thiazole Acetamide Derivatives.” Journal of Cancer Research & Therapeutics, vol. 16, Oct. 2020, pp. 74–81. EBSCOhost, https://doi.org/10.4103/jcrt.JCRT_577_16.

APA

Madhu, L., Telkar, S., Kamath, D., D. Souza, M., Rao, S., Nayak, P., Sarojini, B., Madhu, L. N., D Souza, M. E., Nayak, P. S., & Sarojini, B. K. (2020). Inhibition of Ehrlich ascites cancer, hypoxia-inducible factor-1 alpha, and the kinase insert domain-containing receptor/ -like tyrosine kinase-binding domains of vascular endothelial growth factor by Thiazole Acetamide Derivatives. Journal of Cancer Research & Therapeutics, 16, 74–81. https://doi.org/10.4103/jcrt.JCRT_577_16

Chicago

Madhu, L, Sandeep Telkar, Divyalaxmi Kamath, Melita D. Souza, Shama Rao, Prakash Nayak, B Sarojini, et al. 2020. “Inhibition of Ehrlich Ascites Cancer, Hypoxia-Inducible Factor-1 Alpha, and the Kinase Insert Domain-Containing Receptor/ -like Tyrosine Kinase-Binding Domains of Vascular Endothelial Growth Factor by Thiazole Acetamide Derivatives.” Journal of Cancer Research & Therapeutics 16 (October): 74–81. doi:10.4103/jcrt.JCRT_577_16.